刘定康， 2014年毕业于中国药科大学生物工程专业，获学士学位；2022年以硕博连读方式获中国药科大学生物生物学博士学位。主要研究方向为工程化蛋白质技术药物的设计与开发，以第一作者或共同第一作者在Journal of Controlled Release、British Journal of Pharmacology、Acta Biomaterialia、Cancer Letters等国际学术期刊发表论文5篇，已授权发明专利1项，获2023年江苏省优秀博士学位论文，入选江苏省卓越博士后计划，目前主持国家自然科学基金青年项目1项。
(1) Liu Dingkang#, Bao Lichen#, Zhu Haichao, Yue Yali, Tian Jing, Gao Xiangdong, Yin Jun. Microenvironment-responsive anti-PD-L1×CD3 bispecific T-cell engager for solid tumor immunotherapy, Journal of Controlled Release, 2023, 354: 606-614.
(2) Liu Dingkang#, Rong Haibo#, Chen Ye, Wang Qun, Qian Sijia, Ji Yue, Yao Wenbing, Yin Jun, Gao Xiangdong, Targeted disruption of mitochondria potently reverses multidrug resistance in cancer therapy, British Journal of Pharmacology, 2022, 179(13): 3346-3362.
(3) Liu Dingkang#, Chen Ye#, Wang Qun, Ji Yue, Bao Lichen, Yao Wenbing, Gao Xiangdong, Yin Jun, Tailored protein-conjugated DNA nanoplatform for synergistic cancer therapy, Journal of Controlled Release, 2022, 346: 250-259.
(4) Ji Yue#, Liu Dingkang#, Zhu Haichao, Bao Lichen, Chang Ruilong, Gao Xiangdong*, Yin Jun*. Unstructured Polypeptides as a Versatile Drug Delivery Technology[J]. Acta Biomaterialia. 2023 Jul 1; 164:74-93.
(5) Yin Jun#, Liu Dingkang#, Bao Lichen, Wang Qun, Chen Ye, Hou Shan, Yue Yali, Yao Wenbing, Gao Xiangdong, Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery, Cancer Letters, 2019, 452: 38-50.
(6) 高向东; 尹骏; 刘定康; 姚文兵; 陈烨, 抗肿瘤靶向融合蛋白、其偶联物及用途, 2022-3-22, 中国, ZL 201811632324.1 (发明专利)
